Cataract - Pipeline Review, H1 2020
![](/report_cover/2671/cataract-v-pipeline-review-h1-2013_en.gif)
Cataract - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H1 2020, provides an overview of the Cataract (Ophthalmology) pipeline landscape.
Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H1 2020, provides an overview of the Cataract (Ophthalmology) pipeline landscape.
Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Cataract - Overview
Cataract - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cataract - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cataract - Companies Involved in Therapeutics Development
Calpain Therapeutics Pty Ltd
Cellix Bio Pvt Ltd
CGeneTech (Suzhou China) Co Ltd
Dhp Korea Ltd
Genisphere LLC
Kubota Vision Inc
Plex Pharmaceuticals Inc
ViewPoint Therapeutics Inc
Cataract - Drug Profiles
CAP-1160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-811 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGT-1507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXOPH-65 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DHPNP-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GL-249 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Presbyopia and Cataract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology, Dermatology, Immunology and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cataract - Dormant Projects
Cataract - Discontinued Products
Cataract - Product Development Milestones
Featured News & Press Releases
May 01, 2018: ViewPoint Appoints Dr. Robert Kim as Chief Medical Officer
Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts
May 13, 2012: Calpain Therapeutics Wins Commercialisation Australia Grant To Progress Anti-Cataract Programme
Sep 04, 2011: New Drug Eyes Way To Beat Cataracts
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cataract - Overview
Cataract - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cataract - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cataract - Companies Involved in Therapeutics Development
Calpain Therapeutics Pty Ltd
Cellix Bio Pvt Ltd
CGeneTech (Suzhou China) Co Ltd
Dhp Korea Ltd
Genisphere LLC
Kubota Vision Inc
Plex Pharmaceuticals Inc
ViewPoint Therapeutics Inc
Cataract - Drug Profiles
CAP-1160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-811 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGT-1507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLXOPH-65 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DHPNP-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GL-249 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Presbyopia and Cataract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology, Dermatology, Immunology and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cataract - Dormant Projects
Cataract - Discontinued Products
Cataract - Product Development Milestones
Featured News & Press Releases
May 01, 2018: ViewPoint Appoints Dr. Robert Kim as Chief Medical Officer
Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts
May 13, 2012: Calpain Therapeutics Wins Commercialisation Australia Grant To Progress Anti-Cataract Programme
Sep 04, 2011: New Drug Eyes Way To Beat Cataracts
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Cataract, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Cataract - Pipeline by Calpain Therapeutics Pty Ltd, H1 2020
Cataract - Pipeline by Cellix Bio Pvt Ltd, H1 2020
Cataract - Pipeline by CGeneTech (Suzhou China) Co Ltd, H1 2020
Cataract - Pipeline by Dhp Korea Ltd, H1 2020
Cataract - Pipeline by Genisphere LLC, H1 2020
Cataract - Pipeline by Kubota Vision Inc, H1 2020
Cataract - Pipeline by Plex Pharmaceuticals Inc, H1 2020
Cataract - Pipeline by ViewPoint Therapeutics Inc, H1 2020
Cataract - Dormant Projects, H1 2020
Cataract - Discontinued Products, H1 2020
Number of Products under Development for Cataract, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Cataract - Pipeline by Calpain Therapeutics Pty Ltd, H1 2020
Cataract - Pipeline by Cellix Bio Pvt Ltd, H1 2020
Cataract - Pipeline by CGeneTech (Suzhou China) Co Ltd, H1 2020
Cataract - Pipeline by Dhp Korea Ltd, H1 2020
Cataract - Pipeline by Genisphere LLC, H1 2020
Cataract - Pipeline by Kubota Vision Inc, H1 2020
Cataract - Pipeline by Plex Pharmaceuticals Inc, H1 2020
Cataract - Pipeline by ViewPoint Therapeutics Inc, H1 2020
Cataract - Dormant Projects, H1 2020
Cataract - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Cataract, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
Calpain Therapeutics Pty Ltd
Cellix Bio Pvt Ltd
CGeneTech (Suzhou China) Co Ltd
Dhp Korea Ltd
Genisphere LLC
Kubota Vision Inc
Plex Pharmaceuticals Inc
ViewPoint Therapeutics Inc
Number of Products under Development for Cataract, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
Calpain Therapeutics Pty Ltd
Cellix Bio Pvt Ltd
CGeneTech (Suzhou China) Co Ltd
Dhp Korea Ltd
Genisphere LLC
Kubota Vision Inc
Plex Pharmaceuticals Inc
ViewPoint Therapeutics Inc